Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15641942 | 0.82 | RNPEP (0.50) | CPB2GSRRNPEPFOLH1GABRR1 | |
| SCHEMBL15641943 | 0.82 | RNPEP (0.50) | CPB2GSRRNPEPFOLH1GABRR1 | |
| SCHEMBL19385944 | 0.82 | RNPEP (0.50) | CPB2GSRRNPEPFOLH1GABRR1 | |
| Acetic Acid SCHEMBL919117 | 0.80 | CPB2 (0.49) | CPB2GSRRNPEPFOLH1GABRR1 | |
| SCHEMBL27203661 | 0.80 | GABRR1 (0.33) | GABRR1 | |
| SCHEMBL7593236 | 0.80 | CPB2 (0.49) | CPB2GSRRNPEPFOLH1GABRR1 | |
| SCHEMBL7593232 | 0.80 | CPB2 (0.49) | CPB2GSRRNPEPFOLH1GABRR1 | |
| SCHEMBL27207370 | 0.80 | GABRR1 (0.33) | GABRR1 | |
| SCHEMBL4735950 | 0.80 | GSR (0.52) | CPB2GSRRNPEPFOLH1GABRR1 | |
| SCHEMBL181035 | 0.80 | GSR (0.52) | CPB2GSRRNPEPFOLH1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686442-B2 | PEPTIDE NUCLEIC ACID FOR USE IN VETERINARY MEDICINE | Neilsen, Peter E. (DK) | 2004-02-03 | — | — | US | disclosed |
| US-20030207804-A1 | Modified peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20020188101-A1 | Conjugated peptide nucleic acids having enhanced cellular uptake | ISIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002097134-A2 | MODIFIED PEPTIDE NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1003480-A4 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN PETER EIGIL (DK) | 2002-04-17 | — | — | EP | disclosed |
| US-6350853-B1 | PEPTIDE NUCLEIC ACIDS CONJUGATED TO LIPOPHILIC GROUP AND HAVING MODIFIED BACKBONE WHEREIN AMINO ACID SIDE CHAIN IS ATTACHED TO BACKBONE | Nielsen, Peter E. (DK) | 2002-02-26 | — | — | US | disclosed |
| EP-1003480-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN, Peter Eigil (DK) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998053801-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207804-A1 | Modified peptide nucleic acids | NGLY1, PARN, NPPA | CPB2 966/4885GSR 3847/4885RNPEP 28/4885 |
| US-20020188101-A1 | Conjugated peptide nucleic acids having enhanced cellular uptake | SLC1A5, SLC7A1, SLC29A1 | CPB2 1897/4885GSR 2739/4885RNPEP 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.